Viking Therapeutics (VKTX) Total Current Liabilities (2014 - 2026)

Viking Therapeutics has reported Total Current Liabilities for 13 years, with the latest figure at $109.7 million in Q2 2026.

• Quarterly Total Current Liabilities rose 242.89% year-over-year to $109.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $109.7 million (up 242.89% YoY) and the FY2025 annual result came in at $76.7 million, up 179.67% from the prior year.
• Total Current Liabilities advanced to $109.7 million in Q2 2026 per VKTX's latest filing, from $106.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $109.7 million in Q2 2026 and troughed at $11.3 million in Q1 2022.
• A 5-year average of $33.6 million and a median of $23.5 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities plunged 40.28% in 2025, then soared 443.22% in 2026.
• Over 5 years, Total Current Liabilities stood at $21.9 million in 2022, then decreased by 12.81% to $19.1 million in 2023, then soared by 43.26% to $27.4 million in 2024, then jumped by 179.67% to $76.7 million in 2025, then surged by 43.03% to $109.7 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $109.7 million, $106.3 million, and $76.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.